loader image
Saturday, November 29, 2025
71 F
McAllen
- Advertisement -

When does the weight loss plateau occur on drugs like Ozempic, and can you delay it?

Health & Lifestyle
159

Listen to article (english)

Translate to Spanish or other 102 languages!

When is a person likely to reach a weight loss plateau on GLP-1 agonists vs surgery vs dietary interventions? Image for illustration purposes
When is a person likely to reach a weight loss plateau on GLP-1 agonists vs surgery vs dietary interventions? Image for illustration purposes

Medical News Today

- Advertisement -
  • A new study investigated why different obesity treatments, including diets, surgeries and new medications like GLP-1 receptor agonists, such as semaglutide and tirzepatide, lead to varying times at which weight loss plateaus.
  • Utilizing a mathematical model, the research examines how these interventions alter the body’s regulation of energy intake and expenditure, affecting the duration of effective weight loss.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/when-does-the-loss-plateau-occur-on-drugs-like-ozempic-and-can-you-delay-it

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Vaccines for Family & Caregivers 
Next article
Weight-Loss Surgery Before Kidney Transplantation Improves Health & Eligibility of Patients with Obesity & Renal Failure

More Articles

STHS Behavioral Hosting Webinar on Seasonal Depression, Dec. 4

Mega Doctor News It’s common for individuals to experience an emotional downturn during the winter...

AMA Adopts New Public Health Policies to Improve Health of the Nation

The American Medical Association (AMA) gathered physician and medical student leaders from all corners of medicine at its Interim Meeting of the House of Delegates to shape guiding policies on emerging health care topics.

Study Finds Best Strategy for Reducing Belly Fat

Over the last few years, research has shown that having excessive visceral fat — the fat surrounding the abdominal area that protects internal organs — can be detrimental to a person’s health.

FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy

The U.S. Food and Drug Administration approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in the survival motor neuron 1 (SMN1) gene. Itvisma is an adeno-associated virus (AAV) vector-based gene therapy.
- Advertisement -

We feature articles about leading professionals in the medical and healthcare industry in the South Texas area. We are your connection to the medical community!

Pick up a copy of our publication on more than 800 locations Valley-wide.

Contact Us

Office (956) 928-1255

Sales (956) 451-4585

info@tbbmega.com

sales@tbbmega.com

Subscribe

© Mega Doctor News 2025

×